PolyPid Ltd. develops locally administered, controlled-release therapeutics based on its proprietary PLEX drug-delivery technology. The company’s lead product candidate, D-PLEX100, is designed for prevention of surgical site infections in abdominal colorectal surgery, and company updates commonly cover Phase 3 SHIELD II data, pharmacokinetics, FDA interactions, New Drug Application activity, and manufacturing-readiness topics.
PolyPid news also includes financial results, operational highlights, investor-conference participation, and broader pipeline references spanning surgical care, oncology, obesity, diabetes, and other metabolic-disease applications. Recurring disclosures focus on clinical and regulatory progress, product-candidate development, and the financing and business updates typical of a late-stage biopharmaceutical issuer.
PolyPid (Nasdaq: PYPD) will host a virtual Investor Day on October 28, 2026, to outline its long-term growth and pipeline strategy. The event begins at 11:30 a.m. ET and will cover “PolyPid 2030.” Management will update investors on D-PLEX₁₀₀, its candidate for preventing colorectal surgical site infections, whose application is under FDA Priority Review with a November 28, 2026 decision goal date. It will also introduce PD01B, being developed for diabetic foot infections using Kynatrix delivery technology.
Specialist Warren S. Joseph will discuss diabetic foot infections and locally delivered antibiotic therapy. A live question-and-answer session with Joseph and management will follow.
PolyPid (PYPD) announced European Medicines Agency validation of its D-PLEX₁₀₀ application for preventing incisional infections after abdominal surgery. Validation confirms the application is complete and starts formal review by the agency’s Committee for Medicinal Products for Human Use. The application was submitted on September 14, 2026.
The supporting Phase 3 SHIELD II trial met its primary and all key secondary endpoints, demonstrating a 60% relative risk reduction in surgical site infections versus standard of care (p=0.0013). The U.S. application is concurrently under FDA Priority Review, with a November 28, 2026 decision goal date. If approved in Europe, D-PLEX₁₀₀ would receive one marketing authorization valid throughout EU member states.
PolyPid (PYPD) has regained exclusive European commercialization rights for D-PLEX₁₀₀ following the mutually agreed termination of its agreement with ADVANZ PHARMA.
The terminated 2022 agreement covered licensing, distribution and supply in Europe. PolyPid has completed its Phase 3 SHIELD II trial, its New Drug Application submission to the US Food and Drug Administration and its EMA submission. D-PLEX₁₀₀ met the trial’s primary and all key secondary endpoints for preventing surgical site infections. PolyPid also established a North American commercialization partnership with Azurity Pharmaceuticals. The company believes these milestones make D-PLEX₁₀₀ attractive to multinational pharmaceutical companies for Europe and other large markets.
PolyPid (PYPD) will participate in three investor conferences in fall 2026, offering panel appearances, company presentations, and one-on-one investor meetings.
Events include the 5th Annual ROTH Healthcare Opportunities Conference at the Metropolitan Club in New York on September 29, 2026; the Lytham Partners Fall 2026 Investor Conference with a webcasted presentation on September 29 and virtual 1-on-1 meetings on September 30; and the Craig-Hallum 17th Annual Alpha Select Conference at the Sheraton New York Times Square Hotel on November 17, 2026. PolyPid develops long-acting, controlled-release drugs and reports that lead product D-PLEX100 met primary and key secondary endpoints in the Phase 3 SHIELD II trial.
PolyPid (Nasdaq: PYPD) reported second-quarter 2026 results and key regulatory and commercial milestones for D-PLEX₁₀₀ for prevention of surgical site infections in abdominal colorectal surgery.
The FDA accepted the D-PLEX₁₀₀ NDA with Priority Review and set a PDUFA goal date of November 28, 2026, about one quarter earlier than PolyPid’s prior guidance. No filing review issues were identified. PolyPid also signed an exclusive U.S. and Canada commercialization agreement with Azurity Pharmaceuticals, unlocking $30 million in upfront and near-term milestone payments following NDA acceptance and making the company eligible for up to approximately $320 million in total milestones plus tiered royalties from mid-teen to mid-twenties percentages. Azurity will fund additional clinical development for potential label expansion, while PolyPid retains ex-U.S./Canada commercial rights and global manufacturing.
For Q2 2026, PolyPid reported a net loss of $7.8 million ($0.35 per share) versus $10.0 million ($0.78 per share) a year earlier, with operating expenses modestly lower. As of June 30, 2026, cash and cash equivalents were $6.6 million, excluding the $30 million from Azurity. According to PolyPid, its current cash plus expected proceeds from the Azurity agreement should fund operations into 2028.
PolyPid (Nasdaq: PYPD) will release its second quarter 2026 financial results and operational highlights before U.S. market open on Wednesday, August 12, 2026. Management will host a conference call and webcast at 8:30 AM Eastern Time to review results and discuss business operations.
Registration for the call is recommended at least five minutes before start, with a separate webcast link available for listen-only participants. PolyPid is a biopharmaceutical company focused on long-acting, controlled-release drugs; its lead product D-PLEX₁₀₀ met primary and key secondary endpoints in the Phase 3 SHIELD II surgical site infection prevention trial.
PolyPid (Nasdaq: PYPD) reported that the U.S. FDA has accepted for filing and granted Priority Review to its NDA for D-PLEX₁₀₀ to prevent surgical site infections in patients undergoing abdominal colorectal surgery. The FDA set a PDUFA target action date of November 28, 2026, roughly one quarter earlier than PolyPid’s prior first-quarter 2027 guidance, and identified no filing review issues. Priority Review shortens the target review timeline from ten months to about six months.
According to PolyPid, NDA acceptance triggers a $15 million milestone payment from its U.S. and Canada commercial partner Azurity Pharmaceuticals, completing $30 million in upfront and near-term milestones under their exclusive commercialization agreement. D-PLEX₁₀₀ previously met primary and key secondary endpoints in the Phase 3 SHIELD II trial, including a 60% relative risk reduction in SSI incidence, and has Breakthrough Therapy Designation for prevention of SSIs in elective colorectal surgery.
PolyPid (Nasdaq: PYPD) signed an exclusive commercial partnership with Azurity Pharmaceuticals for D-PLEX100 in the U.S. and Canada for prevention of surgical site infections. PolyPid will receive $15 million upfront at signing and a further $15 million upon expected FDA acceptance of the NDA in August 2026, plus eligibility for up to approximately $300 million in additional regulatory, development, and sales-based milestones.
Upon commercialization, PolyPid will manufacture and supply D-PLEX100 to Azurity for a transfer price and receive tiered royalties from mid-teen to mid-twenties percentages. Azurity may fund additional clinical programs for label expansion in North America. PolyPid retains commercial rights outside the U.S. and Canada and full ownership of its PLEX and Kynatrix platforms. The deal follows positive Phase 3 SHIELD II data, including achievement of the primary endpoint and a 60% relative risk reduction at a key secondary endpoint, with a U.S. launch targeted for Q1 2027.
PolyPid (Nasdaq:PYPD) has completed its rolling New Drug Application submission to the U.S. FDA for D-PLEX100, a lead candidate to prevent surgical site infections in colorectal surgery.
The NDA is backed by a Phase 3 trial showing 60% relative SSI risk reduction, with an expected FDA decision in Q1 2027.
PolyPid (Nasdaq:PYPD) announced that its management will participate in investor meetings at the Craig-Hallum 23rd Annual Institutional Investor Conference on Thursday, May 28, 2026, at the Depot Renaissance Hotel in Minneapolis, MN.
Interested investors should contact their Craig-Hallum representative to arrange meetings with PolyPid.